MarginsXMarginsX
Home › Markets › Health Care › ACXP

Acurx Pharmaceuticals Inc. (ACXP)

ACXP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9350
-2.60% on the day
Market cap
$5.7M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerACXP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001736243
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
17.1 months
$9.7M cash at September 30, 2026
Share count, 1 year
+190.5%
2025-11-11 to 2026-11-12 · +780.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These matters raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$9.7M cash; operating cash flow -$1.7M a quarter.Report 2026-09-30
Shares outstanding6,058,135 (2026-11-12); 2,085,363 a year earlier; 13,767,977 three years earlier. 3y figure adjusted for split (1-for-20 overall).Cover page 2026-11-12
Reverse splits, 3 years1; latest 1-for-20 on 2025-08-05Source 2025-08-05
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-16
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCohnReznick LLP, Parsippany, New Jersey, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$2.6M-$2.5M$9.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$2.3M-$1.7M$10.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$1.7M-$1.4M$9.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$1.6M-$1.2M$7.6MNo debt tagsNeeds four quarters10-K 2026-03-12
Q3 2025
2025-09-30
Not filed-$2.0M-$1.9M$5.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$2.2M-$1.7M$6.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$2.1M-$2.1M$4.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$2.8M-$2.3M$3.7MNo debt tagsNeeds four quarters10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-09-17
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-12
Latest current report
FORM 8-K
8-K2026-11-13
Latest proxyDEFA14A2026-09-01

Source: SEC EDGAR submissions feed, 247 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.4%
1 month-20.0%
3 months-35.1%
Year to date-61.4%
1 year-79.7%
From 52-week high-85.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ALZNAlzamend Neuro Inc.$1.18-4.84%$5.7M
BLRXBioLineRx Ltd.$1.15-12.61%$5.7M
APREAprea Therapeutics Inc.$0.4063-2.38%$5.8M
LTRNLantern Pharma Inc.$0.3890-10.18%$5.8M
FBLGFibroBiologics Inc.$0.9034-2.00%$6.1M
JAGXJaguar Health Inc.$0.3864-7.74%$5.2M
CNSPCNS Pharmaceuticals Inc.$3.48+20.42%$5.1M
CVKDCadrenal Therapeutics Inc.$1.40-7.28%$5.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier